High blood pressure (BP) is a prevalent risk factor for cardiovascular disease, affecting more than 72 million people in India and more than 1 billion people worldwide. The renin–angiotensin–aldosterone system (RAAS) has long been recognized to play a significant role in hypertension pathophysiology. Certain agents that modify the RAAS can control blood pressure and improve cardiovascular outcomes. Here we discuss general overview on aliskiren drug as a renin inhibitor.
Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in hypertensive patients after once-daily oral dosing. In short-term studies, it was effective in lowering blood pressure either alone or in combination with valsartan and hydrochlorothiazide, and had a low incidence of serious adverse effects. Warning Aliskiren may cause injury or death to the fetus if you take…
